Literature DB >> 15197467

Biosynthesis of isoprenoids via the non-mevalonate pathway.

W Eisenreich1, A Bacher, D Arigoni, F Rohdich.   

Abstract

The mevalonate pathway for the biosynthesis of the universal terpenoid precursors, isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), is known in considerable detail. Only recently, the existence of a second mevalonate-independent pathway for the biosynthesis of IPP and DMAPP was detected in plants and certain eubacteria. Experiments with 13C and/or 2H-labelled precursors were crucial in the elucidation of this novel route. The pathway is essential in plants, many eubacteria and apicomplexan parasites, but not in archaea and animals. The genes, enzymes and intermediates of this pathway were rapidly unravelled over the past few years. Detailed knowledge about the mechanisms of this novel route may benefit the development of novel antibiotics, antimalarials and herbicides.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197467     DOI: 10.1007/s00018-004-3381-z

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  22 in total

1.  Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years.

Authors:  Michael J Koren; Theodore Feldman; Robert A Mendes
Journal:  Clin Cardiol       Date:  2009-05       Impact factor: 2.882

2.  High-dose atorvastatin after stroke or transient ischemic attack.

Authors:  Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

3.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Authors:  John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Journal:  N Engl J Med       Date:  2005-03-08       Impact factor: 91.245

4.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

5.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.

Authors:  Steven E Nissen; Stephen J Nicholls; Ilke Sipahi; Peter Libby; Joel S Raichlen; Christie M Ballantyne; Jean Davignon; Raimund Erbel; Jean Charles Fruchart; Jean-Claude Tardif; Paul Schoenhagen; Tim Crowe; Valerie Cain; Kathy Wolski; Marlene Goormastic; E Murat Tuzcu
Journal:  JAMA       Date:  2006-03-13       Impact factor: 56.272

6.  Cardiovascular prevention in clinical practice (ESC and German guidelines 2007).

Authors:  Helmut Gohlke; Christian Albus; Detlef Bernd Gysan; Harry W Hahmann; Peter Mathes
Journal:  Herz       Date:  2009-02       Impact factor: 1.443

7.  The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials.

Authors:  Kiranbir Josan; Sumit R Majumdar; Finlay A McAlister
Journal:  CMAJ       Date:  2008-02-26       Impact factor: 8.262

8.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

Authors:  Anne B Rossebø; Terje R Pedersen; Kurt Boman; Philippe Brudi; John B Chambers; Kenneth Egstrup; Eva Gerdts; Christa Gohlke-Bärwolf; Ingar Holme; Y Antero Kesäniemi; William Malbecq; Christoph A Nienaber; Simon Ray; Terje Skjaerpe; Kristian Wachtell; Ronnie Willenheimer
Journal:  N Engl J Med       Date:  2008-09-02       Impact factor: 91.245

9.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Authors:  Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; B Greg Brown; Peter Ganz; Robert A Vogel; Tim Crowe; Gail Howard; Christopher J Cooper; Bruce Brodie; Cindy L Grines; Anthony N DeMaria
Journal:  JAMA       Date:  2004-03-03       Impact factor: 56.272

10.  Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets.

Authors:  Branislav Liska; Ahmed A Khattab; Lutz Herrmann; Mohamed Abdel-Wahab; Ronja Westphal; Ralph Tölg; Volker Geist; Gert Richardt
Journal:  Herz       Date:  2008-09-05       Impact factor: 1.443

View more
  155 in total

1.  Organometallic mechanism of action and inhibition of the 4Fe-4S isoprenoid biosynthesis protein GcpE (IspG).

Authors:  Weixue Wang; Jikun Li; Ke Wang; Cancan Huang; Yong Zhang; Eric Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

Review 2.  'Conserved hypothetical' proteins: prioritization of targets for experimental study.

Authors:  Michael Y Galperin; Eugene V Koonin
Journal:  Nucleic Acids Res       Date:  2004-10-12       Impact factor: 16.971

3.  Structural basis for nucleotide binding and reaction catalysis in mevalonate diphosphate decarboxylase.

Authors:  Michael L Barta; William J McWhorter; Henry M Miziorko; Brian V Geisbrecht
Journal:  Biochemistry       Date:  2012-07-06       Impact factor: 3.162

4.  A closer look at the spectroscopic properties of possible reaction intermediates in wild-type and mutant (E)-4-hydroxy-3-methylbut-2-enyl diphosphate reductase.

Authors:  Weiya Xu; Nicholas S Lees; Dominique Hall; Dhanushi Welideniya; Brian M Hoffman; Evert C Duin
Journal:  Biochemistry       Date:  2012-06-07       Impact factor: 3.162

5.  Vitamin B6 biosynthesis in higher plants.

Authors:  Marina Tambasco-Studart; Olca Titiz; Thomas Raschle; Gabriela Forster; Nikolaus Amrhein; Teresa B Fitzpatrick
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-12       Impact factor: 11.205

6.  Enzyme-driven speciation: crystallizing Archaea via lipid capture.

Authors:  Jian Payandeh; Emil F Pai
Journal:  J Mol Evol       Date:  2007-01-25       Impact factor: 2.395

7.  1-Hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate reductase (IDS) is encoded by multicopy genes in gymnosperms Ginkgo biloba and Pinus taeda.

Authors:  Sang-Min Kim; Tomohisa Kuzuyama; Akio Kobayashi; Tomoki Sando; Yung-Jin Chang; Soo-Un Kim
Journal:  Planta       Date:  2007-09-01       Impact factor: 4.116

8.  Biosynthesis of salvinorin A proceeds via the deoxyxylulose phosphate pathway.

Authors:  Lukasz Kutrzeba; Franck E Dayan; J'Lynn Howell; Ju Feng; José-Luis Giner; Jordan K Zjawiony
Journal:  Phytochemistry       Date:  2007-06-14       Impact factor: 4.072

9.  Paludisphaera soli sp. nov., a new member of the family Isosphaeraceae isolated from high altitude soil in the Western Himalaya.

Authors:  Rishabh Kaushik; Meesha Sharma; Kumar Gaurav; U Jagadeeshwari; A Shabbir; Ch Sasikala; Ch V Ramana; Maharaj K Pandit
Journal:  Antonie Van Leeuwenhoek       Date:  2020-09-16       Impact factor: 2.271

10.  Two copies of 4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol kinase (CMK) gene in Ginkgo biloba: molecular cloning and functional characterization.

Authors:  Sang-Min Kim; Yeon-Bok Kim; Tomohisa Kuzuyama; Soo-Un Kim
Journal:  Planta       Date:  2008-07-31       Impact factor: 4.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.